On December 8, 2021, the U.S. Food and Drug Administration issued emergency use authorization for tixagevimab/cilgavimab, known as EvusheldTM.  This is a long-acting monoclonal antibody combination against SARS-CoV-2 given every 6 months as pre-exposure prophylaxis for people who are high risk and do not mount an antibody response to COVID vaccine or cannot get any COVID vaccine due to anaphylaxis. There is a note for a small signal of cardiac risk in patients receiving it who, though, had preexisting cardiac history or preexisting cardiac risk factors.

According to Dr. Lionakis, this antibody combination could be an option for APS-1/APECED patients who either had anaphylaxis to the COVID vaccine and as a result cannot receive it, or they are on certain immunosuppressive medications (recent rituximab for example) and received the vaccine series but did not mount antibody responses and are at high risk for SARS-CoV2 exposure.

This is another tool in our tool box as we seek to protect our rare community. We encourage you to share this information with your local care teams.

We’ll continue to post COVID updates here. Check back often.

Leave a Reply

Your email address will not be published. Required fields are marked *